I-MAK Defends Integrity of Its Patent Data in Response to Tillis Letter

β€œAt the time of writing in 2018, 11 out of the 12 drugs did not have any generic or biosimilar competition in the United States. Even the drug that did have competition (Remicade) at the time of writing was limited to only one competitor.” I-MAK letter The Initiative for Medicines, Access & Knowledge (I-MAK) has … Read more